Immunovant Halts IMVT-1402 Development in Cutaneous Lupus After Phase 2 Proof-of-Concept Miss
核心洞察
Immunovant will discontinue development of the anti-FcRn (搜索) antibody IMVT-1402, or imeroprubart (搜索), in cutaneous lupus erythematosus (搜索) after a proof-of-concept trial missed its primary endpoint.
The randomized, double-blind, placebo-controlled study enrolled 57 adults and measured percentage change from baseline in CLASI-A score at Week 12, without reaching statistical significance.
Numerical trends favored IMVT-1402 over placebo across several endpoints, and patients with greater IgG reductions were more likely to show improved clinical responses.
Immunovant, a majority-owned subsidiary of Roivant (搜索), is discontinuing development of IMVT-1402 (imeroprubart (搜索)) in cutaneous lupus erythematosus (搜索) (CLE) after a proof-of-concept study failed to meet its primary endpoint. The company said the decision reflects both the clinical results and the competitive landscape in the indication.
Trial Design and Primary Endpoint
The randomized, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus (搜索). The primary endpoint measured the percentage change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity, or CLASI-A, score at Week 12. The study did not achieve statistical significance on that measure.
IMVT-1402 is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn (搜索)), a mechanism designed to reduce circulating immunoglobulin G. Immunovant describes itself as a clinical-stage immunology company focused on anti-FcRn technology for autoimmune diseases.
Secondary Signals and Safety
Despite the primary endpoint miss, Immunovant reported numerical trends favoring IMVT-1402 over placebo across several endpoints. The company also reported that patients who achieved greater reductions in immunoglobulin G, or IgG, levels were more likely to show improved clinical responses, a finding consistent with the drug's mechanism of action.
The safety and tolerability profile of IMVT-1402 in the trial was consistent with previous studies, according to the company.
"On behalf of everyone at Immunovant, I want to thank the patients living with CLE who volunteered for this study and the investigators and clinical site teams who conducted it with such care," said Eric Venker, M.D., Pharm.D., Chief Executive Officer of Immunovant.
Development Continues in Other Autoimmune Indications
The decision does not affect Immunovant's development of IMVT-1402 in other autoimmune indications. The drug remains in clinical development for Graves' disease (搜索), difficult-to-treat rheumatoid arthritis (搜索), myasthenia gravis (搜索), chronic inflammatory demyelinating polyneuropathy (搜索) and Sjogren's disease (搜索). Immunovant said timelines for its other clinical development programs remain on track.
Roivant (搜索), a commercial-stage biopharmaceutical company, advances its pipeline through subsidiaries it calls "Vants." Beyond IMVT-1402, the pipeline includes LISRAYA (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 that is FDA-approved for the treatment of dermatomyositis in adult patients and is in late-stage development for non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris, as well as mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease.